NeRRe Therapeutics is developing orvepitant, a neurokinin (NK)-1 receptor antagonist, as a first in class, once daily breakthrough treatment for cough hypersensitivity disorders. Having demonstrated proof of efficacy in patients with refractory or unexplained cough, NeRRe will now continue development in chronic cough caused by the rare and terminal lung disease idiopathic pulmonary fibrosis (IPF). A dominant feature of this severe progressive respiratory disease in a high proportion of patients is an uncontrolled and persistent cough which is disabling for these terminally ill patients. The cough is often refractory to medical therapy and there are no approved treatments. Idiopathic pulmonary fibrosis has been designated an orphan disease in both Europe and the USA.
Location: United Kingdom, England, Stevenage
Employees: 11-50
Total raised: $56.22M
Founded date: 2012
Investors 4
| Date | Name | Website |
| - | Forbion | forbion.co... |
| - | OrbiMed | orbimed.co... |
| - | Advent Lif... | adventls.c... |
| - | Fountain H... | fh-partner... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 07.07.2021 | Series B | $27.65M | - |
| 05.01.2017 | Series B | $28.57M | - |
Mentions in press and media 9
| Date | Title | Description |
| 07.07.2021 | NeRRe Therapeutics raises £20 million in a Series B2 financing round | NeRRe Therapeutics, a clinical-stage company developing orvepitant, its wholly-owned neurokinin-1 (NK-1) antagonist, as a first in class treatment for disabling chronic cough caused by reflex hypersensitivity disorders, today announces it h... |
| 07.07.2021 | NeRRe Therapeutics raises £20 million in a Series B2 financing round | NeRRe Therapeutics raises £20 million in a Series B2 financing round New funds to evaluate orvepitant as a treatment for the disabling chronic cough associated with idiopathic pulmonary fibrosis (IPF). New investor Columbus Venture Partners... |
| 07.07.2021 | NeRRe Therapeutics raises £20 million in a Series B2 financing round | Stevenage, UK, 7 July 2021 – NeRRe Therapeutics, a clinical-stage company developing orvepitant, its wholly-owned neurokinin-1 (NK-1) antagonist, as a first in class treatment for disabling chronic cough caused by reflex hypersensitivity di... |
| 07.07.2021 | NeRRe nabs £20M to test chronic cough drug in patients with a fatal lung disease | Patients who have the rare and fatal lung disorder idiopathic pulmonary fibrosis (IPF) have an uncontrolled and persistent cough that’s unresponsive to any therapies. NeRRe Therapeutics has clinical data suggesting its experimental drug red... |
| 05.01.2017 | Term Sheet — Thursday, January 5 | THE 21 BEST TECH IPOS of 2016, ETC Visions: SoftBank has been purposely opaque about many aspects of Vision Fund, its $100 billion (!) tech investment fund, in part, because the fund isn’t closed yet and general solicitation rules prevent i... |
| 05.01.2017 | GSK spinout bags £23M to take NK antagonists into phase 2 | NeRRe Therapeutics has raised £23 million ($28 million) in a Series B backed by new investors Fountain Healthcare Partners, Forbion Capital Partners and OrbiMed. The GlaxoSmithKline spinout will use the money to take two neurokinin receptor... |
| 05.01.2017 | NeRRe Therapeutics Raises £23M in Series B Financing | NeRRe Therapeutics, a Stevenage, England, UK-based clinical-stage company, raised £23m in Series B financing. The round was led by new investor Fountain Healthcare Partners, and co-led by Forbion Capital Partners and OrbiMed. Existing inves... |
| 05.01.2017 | Pieris soars on $31M-plus checkpoint development deal; Luca Santarelli takes helm at Therachon | • Boston-based Pieris $PIRS has inked a deal to work with France’s Servier on some bispecific checkpoint development programs. The deal comes with a $31 million upfront and $338 million in milestones for their progress on PRS-3... |
| - | NeRRe nabs £20M to test chronic cough drug in patients with a fatal lung disease | Patients who have the rare and fatal lung disorder idiopathic pulmonary fibrosis (IPF) have an uncontrolled and persistent cough that’s unresponsive to any therapies. NeRRe Therapeutics has clinical data suggesting its experimental drug red... |